Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spebrutinib - Celgene

Drug Profile

Spebrutinib - Celgene

Alternative Names: AVL-292; CC-292

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Acrylamides; Aniline compounds; Antineoplastics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Chronic lymphocytic leukaemia
  • No development reported Cancer; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 30 May 2019 Phase-I development in Chronic-lymphocytic-leukaemia (Combination therapy, Second-line therapy or greater) is still underway in USA (PO) (NCT01732861)
  • 23 Jan 2019 Celgene Corporation completes a phase Ib trial for Chronic lymphocytic leukaemia (combination therapy, second-line therapy or greater) in USA and Austria (NCT01732861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top